Latest Period
Q4 2025
Security Snapshot
Day One Biopharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (DAWN) Institutional Ownership
CUSIP: 23954D109
13F Institutional Holders and Ownership History from Q2 2021 to Q1 2026
Institutions Reporting
183
Shares (Excl. Options)
81,407,211
Price
$9.32
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- DAWN
- Shares outstanding
- 103,269,345
- Price per share
- $21.47
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 81,407,211
- Total reported value
- $758,405,136
- % of total 13F portfolios
- 0%
- Share change
- -4,405,314
- Value change
- -$19,414,544
- Number of holders
- 183
- Price from insider filings
- $21.47
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- DAWN - Day One Biopharmaceuticals, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 23954D109.
- 183 institutions reported positions in Q4 2025.
- 4 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 183 to 62 between Q4 2025 and Q1 2026.
- Reported value moved from $758,405,136 to $294,220,014.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 183 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 23954D109?
CUSIP 23954D109 identifies DAWN - Day One Biopharmaceuticals, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 23954D109:
Significant Owners of Day One Biopharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (DAWN) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 5.8% | +22% | $38,061,315 | +$6,751,002 | 5,849,917 | +22% | BlackRock, Inc. | 30 Jun 2025 |
| GLAZER CAPITAL, LLC | 5.4% | $64,576,985 | 5,615,390 | Glazer Capital, LLC | 12 Mar 2026 | |||
| Vestal Point Capital, LP | 5.1% | $55,068,000 | 5,200,000 | Vestal Point Capital, LP | 31 Dec 2025 | |||
| FMR LLC | 0% | -93% | $506,835 | -$122,065,810 | 23,640 | -100% | FMR LLC | 31 Mar 2026 |
As of 31 Dec 2025, 183 institutional investors reported holding 81,407,211 shares of Day One Biopharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (DAWN). This represents 79% of the company’s total 103,269,345 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Day One Biopharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (DAWN) together control 64% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.6% | 8,837,574 | -1.8% | 0% | $82,366,188 |
| Atlas Venture Life Science Advisors, LLC | 6.2% | 6,412,560 | -0.28% | 6.9% | $59,765,059 |
| VANGUARD GROUP INC | 6.1% | 6,282,376 | +1.6% | 0% | $58,551,745 |
| FMR LLC | 5.5% | 5,717,008 | -43% | 0% | $53,282,512 |
| Vestal Point Capital, LP | 5% | 5,200,000 | +94% | 1.8% | $48,464,000 |
| STATE STREET CORP | 4.2% | 4,289,566 | +32% | 0% | $39,978,755 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3.6% | 3,723,131 | -21% | 0.44% | $34,699,581 |
| Pictet Asset Management Holding SA | 2.9% | 2,990,801 | +26% | 0.03% | $27,874,265 |
| AIGH Capital Management LLC | 1.9% | 1,992,021 | +31% | 5.5% | $18,565,635 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 1,877,838 | +6.6% | 0% | $17,504,632 |
| Hudson Bay Capital Management LP | 1.6% | 1,700,000 | +29% | 0.09% | $15,844,000 |
| MORGAN STANLEY | 1.5% | 1,550,274 | +19% | 0% | $14,448,557 |
| GOLDMAN SACHS GROUP INC | 1.5% | 1,506,234 | +9.8% | 0% | $14,038,100 |
| Balyasny Asset Management L.P. | 1.4% | 1,489,924 | +7.6% | 0.03% | $13,886,092 |
| Qube Research & Technologies Ltd | 1.4% | 1,486,562 | +27% | 0.02% | $13,854,758 |
| CITADEL ADVISORS LLC | 1.3% | 1,359,613 | +105% | 0.01% | $12,671,593 |
| MILLENNIUM MANAGEMENT LLC | 1.3% | 1,349,919 | +95% | 0.01% | $12,581,245 |
| RENAISSANCE TECHNOLOGIES LLC | 1.3% | 1,305,084 | +44% | 0.02% | $12,163,383 |
| Jefferies Financial Group Inc. | 1.1% | 1,121,502 | 0.09% | $10,452,399 | |
| BANK OF AMERICA CORP /DE/ | 1% | 1,083,818 | -9.1% | 0% | $10,101,185 |
| DIMENSIONAL FUND ADVISORS LP | 1% | 1,037,312 | -15% | 0% | $9,666,870 |
| DAFNA Capital Management LLC | 0.97% | 999,163 | 0% | 2.2% | $9,312,199 |
| JANE STREET GROUP, LLC | 0.82% | 845,154 | +203% | 0.01% | $7,876,835 |
| MAK CAPITAL ONE LLC | 0.8% | 826,205 | -43% | 1% | $7,700,231 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.71% | 737,660 | +2457% | 0.01% | $6,874,991 |
Institutional Holders of Day One Biopharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (DAWN) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 13,725,442 | $294,220,014 | -$4,243,837 | $21.44 | 62 |
| 2025 Q4 | 81,407,211 | $758,405,136 | -$19,414,544 | $9.32 | 183 |
| 2025 Q3 | 85,449,652 | $602,397,711 | -$3,520,489 | $7.05 | 169 |
| 2025 Q2 | 86,186,499 | $560,206,343 | -$67,566,968 | $6.50 | 173 |
| 2025 Q1 | 94,058,917 | $745,890,533 | -$40,487,714 | $7.93 | 183 |
| 2024 Q4 | 93,739,417 | $1,187,690,667 | -$5,879,821 | $12.67 | 163 |
| 2024 Q3 | 92,050,053 | $1,283,687,781 | +$239,491,695 | $13.93 | 165 |
| 2024 Q2 | 74,705,046 | $1,029,464,955 | +$17,373,333 | $13.78 | 155 |
| 2024 Q1 | 72,782,347 | $1,202,300,406 | -$58,498,635 | $16.52 | 147 |
| 2023 Q4 | 76,570,666 | $1,117,957,204 | -$50,224,829 | $14.60 | 138 |
| 2023 Q3 | 77,547,732 | $951,517,363 | -$22,223,998 | $12.27 | 127 |
| 2023 Q2 | 78,803,713 | $941,011,552 | +$208,122,003 | $11.94 | 136 |
| 2023 Q1 | 61,209,087 | $818,137,120 | -$10,189,943 | $13.37 | 122 |
| 2022 Q4 | 59,797,551 | $1,286,831,022 | -$37,719,296 | $21.52 | 105 |
| 2022 Q3 | 60,343,678 | $1,208,648,617 | +$24,007,409 | $20.03 | 87 |
| 2022 Q2 | 59,307,013 | $1,061,573,186 | +$302,547,160 | $17.90 | 80 |
| 2022 Q1 | 43,302,427 | $429,553,897 | +$13,144,675 | $9.92 | 66 |
| 2021 Q4 | 41,477,196 | $698,277,000 | +$74,959,681 | $16.85 | 57 |
| 2021 Q3 | 19,043,827 | $450,147,328 | +$32,649,130 | $23.73 | 43 |
| 2021 Q2 | 17,724,839 | $401,085,000 | +$401,084,962 | $22.77 | 32 |